Objective: To perform a pharmacoeconomic analysis on the treatment of chronic obstructive pulmonary disease (COPD) with the addition of tiotropium bromide. Methods: Pharmacoeconomic modeling was performed utilizing the efficacy of tiotropium bromide from the literature on different settings and severity of COPD. Reductions in exacerbations, hospitalizations, and number of exacerbation days per year were derived from these studies. Cost of drug treatment, exacerbations, hospitalization, and loss of income were derived from local data in Singapore and reported in Singapore dollars (US$1 ¼ S$1.71). A model was constructed to calculate the impact of one-year treatment with tiotropium bromide, and the results were reported for the total incremental cost per year, cost per year needed to reduce one hospitalization in one year, and cost-savings from hospitalizations in one year. Sensitivity analysis were performed for different number of patients treated per year, differing cost of hospitalization, different cost for tiotropium bromide, different impact of tiotropium bromide on clinical outcomes, and the different amount of substitution drug utilized in the comparator group.
Introduction
Chronic obstructive pulmonary disease (COPD) is a common condition that leads to frequent hospitalizations. It was responsible for 8600 hospital admissions in 2002 in Singapore, being the eighth most common cause of admission. 1 This led to 570 deaths in 2002, and was the seventh most common cause of death. 1 A new medication, tiotropium bromide, provided in a Handihaler TM device, has been shown to improve lung function, improve quality of life and reduce dyspnea, reduce the number of COPD exacerbations, and reduce the number of hospitalizations in randomized control trials against placebo. 2, 3 However, its local usage has been hampered by the cost which is S$90.60 for 30 doses of tiotropium bromide. This perceived high drug acquisition cost has led to different hospitals limiting the usage of the drug, even though a recent pharmacoeconomic study in the US setting concluded that the total healthcare cost minus the drug acquisition cost would lead to a cost saving of US$1043 if tiotropium bromide was used in the treatment for one year. 4 The Netherlands and Belgium study 5 which did include the drug acquisition cost concluded that there was an increased cost of 180 Euros per patient per year with better health outcomes if tiotropium bromide was substituted for ipratropium bromide.
We have therefore conducted a simple pharmacoeconomic analysis using local data and cost to derive a potential result from this new drug.
Methods
The clinical benefits of tiotropium bromide in differing severities of COPD were derived from three published studies 2, 3, 6 compared to placebo and shown in Table 1 . All cost is shown as Singapore dollars (current exchange rate to US$ is US$1 ¼ S$1.71).
The hospitalization cost is calculated from the published data from Singapore's Ministry of Health subsidized COPD patients hospitalized between 1 July 2003 and 1 May 2004 for four hospitals (Changi General Hospital, National University Hospital, Singapore General Hospital and Tan Tock Seng Hospital), 1 using the average of the median charge and assuming that there was a 60% subsidy for this class of patient. Average length of stay was assumed to be 4.2 days based on the average of the four hospitals for these patients. The sum was then assumed to be the cost of each hospitalization. In addition to data from the Ministry of Health, the average cost of hospitalization for COPD patients in the year 2003 was also available from our cluster (National Healthcare Group) database (consisting of three hospitals, National University Hospital, Tan Tock Seng Hospital and Alexandra Hospital) covering a total of 2104 cases. Acquisition cost for the drugs are based on the current cost at National University Hospital. All the cost assumptions are tabulated in Table 2 .
ARTICLE IN PRESS
The model was then performed on different number of patients (1000, 2000 and 5000). Incremental cost per year of tiotropium bromide treatment was calculated by taking the total cost of using the drug for one year minus the total cost of ipratropium bromide for one year (substituting the drugs) minus the reduction in hospitalization cost for one year minus the reduction in cost of treating exacerbations minus the reduction in the loss of income. One assumes that the other treatment costs are not altered, while one presumes that if tiotropium bromide is being used, the short-acting anticholinergic (ipratropium bromide) would be replaced. Cost to reduce one hospitalization and the savings in hospitalization cost per year were also calculated. The percentage of cost savings from decreasing hospitalization was calculated by dividing the incremental cost per year of tiotropium bromide treatment by the savings in hospitalization cost per year. Sensitivity analysis was performed to look at the influence of the differing impact of the drug, different dosing of ipratopium bromide and the varying cost of hospitalization.
Note that there is no cost provided for improvement in quality of life and reduction in feelings of dyspnea that is significantly higher in tiotropium treated patients. There was also no adjustment for the potential differing cost in hospitalization for those treated with tiotropium bromide as the number of days of hospitalization is also reduced in this group of patients compared to placebo.
2,3

Results
The results of the different assumptions and effects utilized from the different studies are shown in Table 3 (which used Ministry of Health data) and Table 4 (which used National Healthcare Group data). These demonstrate significant cost savings in favor of tiotropium. These apply to the incremental cost per year of tiotropium bromide treatment, to the cost savings in hospitalization per year, and to the cost required to reduce one hospitalization. It is apparent that the cost savings generally increase with the number of patients treated with tiotropium bromide per year. In addition, cost savings are greater in patients with more severe COPD, as evidenced by the largest calculated savings when using data from Brusasco et al. 3 in which the COPD was most severe (mean forced expiratory volume in 1 s (FEV 1 ) 11-12% of predicted).
The overall cost savings vary depending on the cost for hospitalization (Fig. 1) , the usage of ipratropium bromide (Fig. 2) , and the potential different acquisition cost of tiotropium bromide in other institutions (Fig. 3) . The contribution to the overall cost savings from decreasing hospitalization costs varies depending on the different clinical effects of the studies utilized (Casaburi et al., 2 Brusasco et al. 3 or Niewoehner et al. 6 ). This varied from 32% to 72% using Ministry of Health data (Table  3) and from 41% to 79% using National Healthcare Group data (Table 4 ). In addition, although no cost savings were found utilizing data from Niewoehner et al. 6 (note positive rather than negative value for incremental cost in both Tables 3 and 4) , this would not be the case if the assumed use of ipratropium bromide was increased from eight doses per day. E.g. if it were assumed that 16 doses of ipratropium bromide were used per day, the cost savings for tiotropium bromide use per year per 1000 patients will be $145,396.88 using Ministry of Health figures and À$196,649.00 using National Healthcare Group figures.
Discussion
This analysis has demonstrated the potential cost savings to the healthcare system if tiotropium bromide is utilized for severe COPD patients. Even Table 2 Cost assumptions for chronic obstructive pulmonary disease management in Singapore. though there is an increase in cost of acquiring the drug, the significant clinical benefits, especially in terms of reduction of hospitalizations, lead to an overall in cost saving for most of the analysis performed. It is important to note that there has been no calculation of the monetary worth of improved quality of life in favor of tiotropium bromide. Our study is consistent with the other two previous studies 4, 5 in estimating the benefits of tiotropium, although it is distinct from the previous studies because it uses clinical effects from three different trials with different clinical effects. 
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Hospitalization cost per episode (S$)
Incremental cost from tiotropium use per yr for 5,000 patients Figure 1 Sensitivity analysis varying the cost of hospitalization, assuming the clinical benefits from the Brusasco et al. No of doses of ipratropium per day Incremental cost per year for 5,000 on tiotropium Figure 2 Sensitivity analysis performed by varying the dose of ipratropium bromide used as assumed in the placebo group, using the clinical effects from the Brusasco et al. 3 study, and the cost of S$2140 per hospitalization based on National Healthcare Group data.
The US study 4 used the data from the Casaburi et al. study, and did not factor in the cost of tiotropium bromide and estimated the mean healthcare total cost per patient was reduced by US$1043 (1999 valuation) in one year. Furthermore, they calculated that hospital admission costs were 48% of total direct medical cost. Our study did not make an allowance for the difference in baseline medications that was present in the two treated groups as was done in the US study. For instance, there were more patients on inhaled corticosteroids in the tiotropium-treated group then placebo. Furthermore, we made the assumption that all our patients were on anticholinergics and these were then discontinued when they are treated with tiotropium, and all the placebo patients would be taking anticholinergics. In fact, in the Casaburi et al. 3 study, 55% of the tiotropium group and 59% of the placebo group were taking anticholinergics at baseline. If we had combination b 2 -agonist and anticholinergic (Berodual TM , Boehringer Ingelheim) as the alternative drug instead, the cost savings would be even greater as this costs nearly 40% more than ipratopium bromide alone. The US study also considered differential hospitalization costs because of the different days of ICU utilization in the two groups (0.07 days in the tiotropium bromide group, and 0.11 days in the placebo group), but did not factor this into their calculation. There was also no loss of earnings calculation.
The European study 5 utilized the results from a different trial. 7 We did not use the results from this trial because the difference in the hospitalization rates was not significantly reduced in the tiotropium bromide group although the trend was a substantial reduction. The authors from the European study 5 included intensive care unit costs that were separate from the general ward costs, but this was actually higher amongst the tiotropium bromide-treated group. As this study included the cost of tiotropium bromide, there was an incremental cost effectiveness of 667 Euros per exacerbation avoided.
It is important that the assumptions utilized in this study and others are fully understood. The clinical benefit of tiotropium appears to be greatest in the more severely ill COPD patients measured by baseline FEV 1 measurements as was the case in the Brusasco et al. 3 study. As such, the analysis is dependent on the clinical effects as documented under those conditions. The sensitivity analysis on the cost of tiotropium bromide gives some idea on its potential impact on cost-savings. It appears that the beneficial effect is negated as the cost of tiotropium bromide increases, and if it is more than S$180 per 30 doses, there appears to be an
ARTICLE IN PRESS
Changing the cost of tiotropium bromide -$5,000,000.00 -$4,000,000.00 -$3,000,000.00 -$2,000,000.00 -$1,000,000.00 $0.00 $1,000,000.00 $2,000,000.00 $3,000,000.00 $80.00 $100.00 $120.00 $140.00 $160.00 $180.00 $200.00 $220.00 $240.00 $260.00
Cost of tiotropium bromide per 30 doses (S$)
Incremental cost per year Figure 3 Sensitivity analysis varying the acquisition cost for tiotropium bromide assuming the clinical effects from the Brusasco et al. 3 study, and the cost of S$2140 per hospitalization based on National Healthcare Group data.
incremental cost for the beneficial effect rather than a cost savings. Importantly, the percentage that is contributed by the hospitalization cost to the total cost savings varies as the clinical effect changes. It may be as low as 32% to as high as 79%. In addition, it should be noted that in our calculations, it was assumed that other treatment costs were not altered with the use of tiotropium bromide. Conceivably, it may be speculated that with the reduction in hospitalization due to tiotropium, the burden on the rest of the healthcare system may increase. The impact of this, however, will likely be small, given that treatment of COPD with tiotropium decreases not only hospitalization but also exacerbations and symptoms.
It is also useful to consider some of the other cost studies with other medications utilized in COPD treatment. Friedman et al. 8 looked at the cost comparison for albuterol versus ipratropium bromide versus albuterol plus ipratropium bromide in 1076 COPD patients with an average FEV 1 of 35.1% over a 85-day period. They showed that there was a cost benefit advantage based on 1998 prices for both ipratropium bromide alone (US$113) or ipratropium bromide plus albuterol (US$72) due to decreased hospitalization costs. A Canadian study 9 looking at the effect of the combination inhaler including ipratropium bromide plus albuterol compared to the drugs given separately also demonstrated an annual cost savings for the province of Saskatchewan estimated at about C$103,468 in favor of the combination inhaler.
This local data will help healthcare managers make appropriate decisions when considering the inclusion of tiotropium bromide to their hospital formularies. It should also provide physicians with the tools to argue for better treatment for their COPD patients, and provide cost estimates for the impact on this new treatment beyond the simple concern about increased drug expenditures. As such, our study allows us to draw the conclusion that tiotropium bromide improves patient's clinical outcomes, and still provides a cost-saving for the overall economy, which is the strongest argument for its utilization.
Conclusion
Tiotropium bromide should be a cost effective treatment for severe COPD patients leading to significant cost savings in the Singapore setting. This finding holds true for the majority of the sensitivity analysis.
